Trial Profile
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 Mg Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Europe
- 20 Jun 2011 Mean 24-hour ambulatory BP results (stratified by baseline ABP) presented at the 21st European Meeting on Hypertension.
- 20 Jun 2011 Target blood pressure results presented at the 21st European Meeting on Hypertension.
- 13 Jun 2009 Results were presented at the 19th European Meeting on Hypertension.